KalVista Pharmaceuticals, Inc. Income Statement

Ask AI

Financial Statements

In millions of USD; shares in millions, except per-share amounts

	FY2025 12 months to Apr 30, 2025	FY2024 12 months to Apr 30, 2024	FY2023 12 months to Apr 30, 2023	FY2022 12 months to Apr 30, 2022	FY2021 12 months to Apr 30, 2021
Operating Expenses:
Research and development
General and administrative
Total operating expenses
Operating loss
Other income:
Interest income
Interest (expense)
Foreign currency exchange gain (loss)
Other income (expenses), net
Total other income
Loss before income taxes
Income tax (benefit) expense
Net loss
Other comprehensive (loss) income:
Foreign currency translation loss
Unrealized holding gain on marketable securities
Reclassification adjustment for realized (gain) loss on available for sale securities included in net loss
Total other comprehensive (loss):
Comprehensive loss
Net loss per share, basic and diluted
Weighted average common shares outstanding, basic and diluted
Net loss per share, basic
Net loss per share, diluted
Weighted average common shares outstanding, basic
Weighted average common shares outstanding, diluted

Comments